Stratos Wealth Partners, Ltd. Protalix Bio Therapeutics, Inc. Transaction History
Stratos Wealth Partners, Ltd.
- $7.06 Billion
- Q2 2025
A detailed history of Stratos Wealth Partners, Ltd. transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Stratos Wealth Partners, Ltd. holds 350,000 shares of PLX stock, worth $574,000. This represents 0.01% of its overall portfolio holdings.
Number of Shares
350,000
Previous 346,400
1.04%
Holding current value
$574,000
Previous $886,000
41.53%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding PLX
# of Institutions
68Shares Held
8.72MCall Options Held
168KPut Options Held
31.4K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.62MShares$2.65 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.08MShares$1.77 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA826KShares$1.36 Million0.0% of portfolio
-
Connor, Clark & Lunn Investment Management Ltd.496KShares$813,7940.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA485KShares$795,0680.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $81.6M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...